Wesfarmers to sell Coregas for $770m to Nippon Sanso Holdings
Wesfarmers (ASX:WES) has announced an agreement to sell its Coregas business to a subsidiary of Nippon Sanso Holdings Corporation for $770m.
Read MoreTag: WES
Analysis of Mineral Resources, Woolworths, Wesfarmers, Qantas
Fund Manager Chris Pedersen discusses Mineral Resources, Woolworths Group, Wesfarmers and Qantas Airways.
Read MoreUptick in Wesfarmers dividend despite retail sector slump
In defiance of prevailing market trends characterized by sluggish retail sales and dwindling profits, Wesfarmers, propelled by the stellar performance of its Kmart retail group comprising Kmart and Target, has announced a commendable uptick in its interim dividend.
Read MoreWesfarmers forges ahead with lithium expansion despite industry challenges
In the face of industry-wide concerns and cutbacks, Wesfarmers (ASX:WES) has demonstrated unwavering confidence in its lithium venture, as evidenced by its recent interim results announcement.
Read MoreMarket observations, Brambles, Wesfarmers, ASX
Fund Manager Chris Pedersen discusses markets leading up to the new year, Brambles, Wesfarmers and ASX.
Read MoreWesfarmers announces increased dividend despite second half earnings slowdown
Shareholders in Wesfarmers (ASX:WES), the conglomerate that owns Bunnings, Kmart/Target, Officeworks, and a range of industrial enterprises, are set to receive a higher dividend for the fiscal year ending in June, even in the face of a second-half earnings deceleration.
Read MoreWesfarmers matches EC Healthcare’s offer for SILK Laser
After saying it would be disciplined in spending capital, Wesfarmers has surprised by announcing a decision to match the $3.35 per share offer by EC Healthcare for SILK Laser.
Read MoreWesfarmers Boss a Bit of a Bullish Bear
Wesfarmers CEO Ron Scott got a lot of publicity Tuesday for comments about the endtimes of government handouts and ultra-low interest rates.
Read MoreWA Lithium Commitment Remains Unwavering
There’s significant expansion afoot in WA’s lithium industry as companies ignore the nervous nellies and plough on with exploration and processing plans.
Read MoreSetback for WES at Mount Holland Lithium Project
A setback for Wesfarmers at its jointly-owned Mount Holland lithium project in WA, with production delayed by around six months and costs jumping by anywhere up to 20%.
Read MoreFrom Covid to Cost Pressures: Wesfarmers’ Challenging Year
Covid lockdowns saw Wesfarmers post a 2.9% drop in annual profit for the year to June, with unwanted assistance from supply chain bottlenecks and emerging cost pressures.
Read MoreWES – Macquarie rates the stock as Underperform
Rating is downgraded to Underperform from Neutral. Target is reduced to $43.30 from $47.50.
Read MoreBourse Discourse: IGO, WES, NCZ
On the ASX docket Thursday: IGO’s WSA takeover reaches its conclusion; a fairly nondescript investor presentation from Wesfarmers; and an old copper mine gets another life.
Read MoreWES – UBS rates the stock as Buy
The Buy rating and target price of $56.00 are retained.
Read MoreWesfarmers’ Low-Key Lithium Presence On Track
It’s far from a main earnings driver, but a rare update has confirmed that Wesfarmers’ half-owned lithium project in WA remains on track for first production in two years’ time.
Read MoreStock Snippets: WPL, WES, TLS, S32
Another busy day on the Australian bourse. Here’s the latest from some of the companies at the bigger end of town – Woodside Petroleum, Wesfarmers, Telstra and South32.
Read MoreAll Systems Go for Wesfarmers’ API Bid
Wesfarmers’ takeover of Australian Pharmaceutical Industries has been given the greenlight to proceed after getting clearance from the competition regulator, the ACCC.
Read MoreWesfarmers Shares Jump Despite Cagey Update
Wesfarmers shares rose sharply yesterday despite a substantial downgrade for sales growth and profits as Covid Omicron took a toll on sales in two key chains – Kmart and Officeworks.
Read MoreWesfarmers Makes a Stand with API Holding
Wesfarmers’ decision yesterday not to sell its 19% stake in API is seen by most market pundits as effectively being a blocking move against the bid from rival Woolworths.
Read MoreWoolworths Gatecrashes API Party
Shares in API soared more than 16% on Thursday to a high of $1.74 after Woolworths crashed Wesfarmers’ attempt to take control of the company.
Read MoreWES – Credit Suisse rates the stock as Neutral
The Neutral rating is retained. Target is raised to $60.38 from $59.91.
Read MoreAPI Chessboard Moves to a Stalemate
Sigma’s attempt to snatch control of API appears to have been thwarted, with rival bidder Wesfarmers exercising its call option over 19.3% API shares to put it in a dominant blocking position.
Read MoreACCC Signs Off on Bunnings-Beaumont Deal
Competition regulator the ACCC has given the greenlight for Wesfarmers’ hardware chain Bunnings to acquire national tile retailer Beaumont Tiles.
Read MoreSigma Leapfrogs Wesfarmers in Race for API
Sigma Healthcare has come over the top of Wesfarmers and made a non-binding cash and share offer for rival chemist Australian Pharmaceutical Industries that seems to have grabbed the lead in the battle.
Read MoreWES – UBS rates the stock as Neutral
Neutral and $62 target retained.
Read MoreWesfarmers Sweetens API Bid
Wesfarmers seems to have won the hearts and minds of the board and major shareholders of Australian Pharmaceutical Industries (API) with a lift in its proposed offer price from $1.38 cash to $1.55 a share.
Read MoreWES – Citi rates the stock as Sell
Citi continues to have a problem with the valuation, hence the Sell rating remains in place. Target price climbs to $49 from $47.
Read MoreChunky Dividend for Wesfarmers Shareholders
Retail giant Wesfarmers has joined the list of companies rewarding their shareholders, announcing $2.3 billion in dividends after a solid financial year which saw profits jump 16%.
Read MoreAPI Knocks Back “Opportunistic” Wesfarmers Bid
Australian Pharmaceutical Industries has told Wesfarmers to go away after rejecting the non-binding $1.38 a share offer as “opportunistic” and not in the best interests of shareholders.
Read MoreWesfarmers’ API Bid Could Put the Sector in Play
Wesfarmers’ surprise $687 million, $1.38 per share bid for Australian Pharmaceutical Industries (API) could very well re-ignite a brawl over the big retailers getting into the business.
Read MoreWES – Credit Suisse rates the stock as Neutral
The broker retains a Neutral rating and lowers the target to $57.23 from $57.32 after a few minor adjustments to chemicals forecasts.
Read MoreWES – Credit Suisse rates the stock as Neutral
The broker retains a Neutral rating and raises the target of $57.32 from $57.04.
Read MoreWesfarmers on Target for Profitable Year
Amid the sales surges experienced by Wesfarmers’ operations, Target seems to be heading towards a profitable June 30 year for the first time in quite a while.
Read MoreBunnings Nails It Again For Wesfarmers
The fortunes of Wesfarmers are increasingly tied (and the share price for that matter) to the performance of its Bunnings hardware chain, judging by the latest trading update for the Perth based giant.
Read MoreWES – Credit Suisse rates the stock as Upgrade to Outperform from Neutral
Credit Suisse upgrades forecasts, expecting the boost to household goods expenditure will be longer than previously anticipated. Wesfarmers is also positioned to add value through strategic acquisitions in the industrials and home improvement sectors.
Read MoreWindow Opens On Consumer Trends
Consumers shopped in larger quantities, less frequently and increasingly online during the height of the nationwide lockdowns. The question now is: which trends will persist and which stocks will benefit as restrictions ease?
Read MoreOff-Target Retail Chain Sours Strong Result At Wesfarmers
While its Bunnings and Officeworks chains have had a good pandemic, a write-down on the value of its struggling target chain saw Wesfarmers report lower earnings for the year to June.
Read MoreWES – Credit Suisse rates the stock as Neutral
Credit Suisse expects the company’s retail market position and solid trading through the fourth quarter will support the FY20 results, due on August 20.
Read More
